Avivagen Announces Approval in Vietnam

24 February 2022 | Thursday | News

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that Avivagen’s oxidized carotenoid-based feed additive product has received approval for use in Vietnam.
Image Source : Public Domain

Image Source : Public Domain

“We are very excited to secure approval for our product in Vietnam, a critical feed market in Southeast Asia with strong growth potential over the coming years,” says Kym Anthony, Chief Executive Officer, Avivagen. “We continue to make strong in-roads with feed producers across Asia and see considerable opportunity to further grow our presence in the swine and poultry feed markets in Vietnam and across the region.”

Vietnam represents the largest feed market in Southeast Asia according to a report by the US Grains Council, which indicates total annual feed consumption of over 32 MMT in 2020. Additionally, The Grains Council report states that Vietnam is a strong growth market which is expected to surpass 35 MMT of feed within the next few years.i Production within the country is dominated by swine, with feed for swine accounting for approximately 38% of total feed, followed by poultry accounting for 21.6% of total feed. (2020)ii. In addition to swine and poultry Vietnam has a surprisingly large and rapidly growing dairy industry which represents an important third target market segment for use of Avivagen’s product.

“Demand for effective alternatives to antibiotics is growing across all of Southeast Asia,” says Lesley Nernberg, Technical Sales and Marketing Consultant, Asia, Avivagen Inc. “Approval in Vietnam will allow Avivagen to capitalize on a marketplace ready for these types of innovations.”

The use of Avivagen’s product in the Vietnam feed industry is supported by the positive results of two research trials conducted specifically under Vietnamese commercial production conditions. The trials were run in collaboration with the Institute for Animal Sciences for South Vietnam and were conducted with pigs. “The results of these two trials make clear the benefits of Avivagen’s product on improving the health and productivity of piglets. We’re confident that the use of our product in this segment, along with poultry and dairy, will have a significantly positive impact for producers throughout the country,” says Jamie Nickerson, President, Avivagen Inc. “Comparable trials are underway around the world, and we expect many to result in additional regulatory approvals and customer wins over the coming months.”


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in